Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / Belgium

European Innovation Council · Running

ALMA ALMA - Pioneering Smart Lens to Revolutionize Eye Care

Coordinator
Azalea Vision, Belgium
Runs
1 November 2026 to 31 October 2028
Status
Running
EU funding
€2.5m
Total cost
—
Partners
1 organisations in 1 countries
Type
European Innovation Council
Grant agreement
101314858

What the project is doing

In the project's own words, from its summary on CORDIS.

Nearly 5M people in the EU, the UK, and the US are affected by irregular corneas, a condition characterized by imperfections on the corneal surface. Irregular corneas disrupt the smooth, regular structure needed to focus light evenly onto the retina, leading to distorted or blurry vision. This condition can result from various causes, including diseases, injuries, or previous surgeries. Patients with irregular corneas often experience significant visual disturbances and may struggle with glare, halos, and night vision issues.

Treatment options range from spectacles and various contact lenses to more invasive procedures like corneal transplants. The current state-of-the-art solutions, including rigid scleral lenses, often fail to fully address higher order aberrations, leaving patients with persistent vision problems. After 10+ years of research and breakthroughs in smart contact lens design, construction, and operation, Azalea has developed ALMA, the first patented autonomous and adaptable Smart Lens for patients with irregular corneas.

This revolutionary solution integrates advanced light management technology into a scleral lens platform, featuring a dynamic light filter, a custom microchip, and a wireless smart case for charging and disinfection. ALMA provides improved visual quality, enhanced comfort, and real-time adaptation to environmental conditions, offering a new standard of care for patients with irregular corneas. With EIC’s support, Azalea plans to conduct First-in-Human and pivotal clinical trials to obtain CE mark and FDA approvals for the commercialization of the ALMA Smart Lens.

Our initial focus is on the irregular cornea market across Europe, the UK, and the US. This market encompasses a total addressable population of 614k patients with irregular corneas, representing a market opportunity of €3B. The project is expected to significantly impact Azalea, projecting €130M in revenues and reaching 135 employees within 5 years of commercialization.

Topics

Who is involved

OrganisationCityCountryRole
Azalea VisionGandBelgiumCoordinator

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI